Sign up to save your podcasts
Or
Share Alasdair MacGowan on oral treatments for MRSA skin infections
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Alasdair MacGowan on oral treatments for MRSA skin infections
Professor Alasdair MacGowan joins Charlotte Rowbottom, Senior Editor at eClinicalMedicine, to discuss treatment options for skin infections caused by MRSA, antimicrobial stewardship, and their research comparing the safety and efficacy of two therapeutic regimens.
Read the full article:
Oral minocycline plus rifampicin versus oral linezolid for complicated skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus: the AIDA open label, randomized, controlled phase 4 trial
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
View all episodes
By The Lancet GroupProfessor Alasdair MacGowan joins Charlotte Rowbottom, Senior Editor at eClinicalMedicine, to discuss treatment options for skin infections caused by MRSA, antimicrobial stewardship, and their research comparing the safety and efficacy of two therapeutic regimens.
Read the full article:
Oral minocycline plus rifampicin versus oral linezolid for complicated skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus: the AIDA open label, randomized, controlled phase 4 trial
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
More shows like eClinicalMedicine in conversation with
View all
The Lancet Voice
22 Listeners
The Lancet Child & Adolescent Health in conversation with
0 Listeners
The Lancet Digital Health in conversation with
0 Listeners
The Lancet Global Health in conversation with
2 Listeners
The Lancet Oncology in conversation with
2 Listeners
The Lancet Psychiatry in conversation with
0 Listeners
The Lancet Respiratory Medicine in conversation with
1 Listeners
The Lancet in conversation with
0 Listeners
The Lancet Haematology in conversation with
0 Listeners
The Lancet Gastroenterology & Hepatology in conversation with
0 Listeners
The Lancet Diabetes & Endocrinology in conversation with
1 Listeners
The Lancet Infectious Diseases in conversation with
0 Listeners
The Lancet Public Health in conversation with
1 Listeners
The Lancet Microbe in conversation with
0 Listeners
In conversation with...
0 Listeners
eBioMedicine in conversation with
0 Listeners
The Lancet Rheumatology in conversation with
0 Listeners
The Lancet Regional Health in conversation with
0 Listeners
The Lancet Regional Health Americas in conversation with
0 Listeners
The Lancet Primary Care in conversation with
0 Listeners